Research programme: HuMax-CD32b antibodies - Genmab

Drug Profile

Research programme: HuMax-CD32b antibodies - Genmab

Alternative Names: HuMax-CD32b antibody

Latest Information Update: 15 Nov 2013

Price : $50

At a glance

  • Originator Genmab
  • Class Monoclonal antibodies
  • Mechanism of Action Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 15 Nov 2013 Discontinued - Preclinical for Haematological malignancies in Denmark (Parenteral)
  • 18 Mar 2011 No development reported - Preclinical for Haematological malignancies in Denmark (Parenteral)
  • 08 Jan 2008 Preclinical trials in Haematological malignancies in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top